MLANA and melanoma: Collectively, our data showing the improved expansion of MART-1 specific CD8+ effector T cells both from naïve blood and from melanoma-draining SLN support the use of Ad3-based viruses as an in vivo DC-targeting vaccine vehicle in patients with melanoma.